Filing Details

Accession Number:
0000899243-20-017434
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-06-22 19:31:00
Reporting Period:
2020-06-18
Accepted Time:
2020-06-22 19:31:00
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1571498 Epizyme Inc. EPZM Pharmaceutical Preparations (2834) 261349956
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1673802 Matthew Ros C/O Epizyme, Inc., 400 Technology Square
Cambridge MA 02139
See Remarks No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, Par Value $0.0001 Acquisiton 2020-06-18 41,063 $9.12 92,861 No 4 M Direct
Common Stock, Par Value $0.0001 Disposition 2020-06-18 41,063 $20.50 51,798 No 4 S Direct
Common Stock, Par Value $0.0001 Acquisiton 2020-06-18 2,289 $12.45 54,087 No 4 M Direct
Common Stock, Par Value $0.0001 Disposition 2020-06-18 2,289 $22.00 51,798 No 4 S Direct
Common Stock, Par Value $0.0001 Acquisiton 2020-06-18 68,651 $9.58 120,449 No 4 M Direct
Common Stock, Par Value $0.0001 Disposition 2020-06-18 68,651 $21.65 51,798 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2020-06-18 41,063 $0.00 41,063 $9.12
Common Stock Stock Option (Right to Buy) Disposition 2020-06-18 2,289 $0.00 2,289 $12.45
Common Stock Stock Option (Right to Buy) Disposition 2020-06-18 68,651 $0.00 68,651 $9.58
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
110,557 2029-01-23 No 4 M Direct
107,577 2027-02-07 No 4 M Direct
104,787 2026-05-15 No 4 M Direct
Footnotes
  1. The exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.50 per share to $22.00 per share, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. This option was granted on January 24, 2019 pursuant to the Company's 2013 Stock Incentive Plan with respect to 151,620 shares of Common Stock, with 25% vesting on January 24, 2020 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter.
  4. This option was granted on February 8, 2017 pursuant to the Company's 2013 Stock Incentive Plan with respect to 109,866 shares of Common Stock, with 25% vesting on February 8, 2018 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter.
  5. This option is fully vested.